Literature DB >> 20219002

Risk Malignancy Index (RMI) in patients with abnormal pelvic mass: Comparing RMI 1, 2 and 3 in an Australian population.

Ganendra Raj Kader Ali Mohan1, Kenneth Jaaback, Anthony Proietto, Randall Robertson, Donald Angstetra.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20219002     DOI： 10.1111/j.1479-828X.2009.01105.x

Source DB:  PubMed          Journal:  Aust N Z J Obstet Gynaecol        ISSN： 0004-8666            Impact factor:   2.100


× No keyword cloud information.
  4 in total

1.  Validity of Cancer Antigen-125 (CA-125) and Risk of Malignancy Index (RMI) in the Diagnosis of Ovarian Cancer.

Authors:  Khawla Al-Musalhi; Manal Al-Kindi; Fatma Ramadhan; Thuraya Al-Rawahi; Khalsa Al-Hatali; Waad-Allah Mula-Abed
Journal:  Oman Med J       Date:  2015-11

2.  A preliminary study: The sequential use of the risk malignancy index and contrast-enhanced ultrasonography in differential diagnosis of adnexal masses.

Authors:  Li Qiu; Fan Yang; Hong Luo
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

3.  Assessment of the diagnostic value of using serum CA125 and GI-RADS system in the evaluation of adnexal masses.

Authors:  Heng Zheng; Yan Tie; Xi Wang; Yang Yang; Xiawei Wei; Xia Zhao
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

4.  Assessment of Diagnostic Value of Serum Ca-125 and Risk of Malignancy Index Scoring in the Evaluation of Adnexal Masses.

Authors:  Kavita Khoiwal; Anupama Bahadur; Ranjeeta Kumari; Namrata Bhattacharya; Shalinee Rao; Jaya Chaturvedi
Journal:  J Midlife Health       Date:  2019 Oct-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.